TY - JOUR
T1 - AAPM task group report 303 endorsed by the ABS
T2 - MRI implementation in HDR brachytherapy—Considerations from simulation to treatment
AU - Prisciandaro, Joann
AU - Zoberi, Jacqueline
AU - Cohen, Gil'ad
AU - Kim, Yusung
AU - Johnson, Perry
AU - Paulson, Eric
AU - Song, William
AU - Hwang, Ken Pin
AU - Erickson, Beth
AU - Beriwal, Sushil
AU - Kirisits, Christian
AU - Mourtada, Firas
N1 - Funding Information:
The members of AAPM TG # 303 listed below disclose the following potential conflict(s) of interest related to subject matter or materials presented in this document. K.‐P. H. receives research funding from General Electric Healthcare. J. P. has received funding for a nonclinical evaluation agreement with Varian Medical Systems, Inc. She was also involved in an unfunded, nonclinical evaluation agreement with C4 Imaging LLC. Y. K. receives funding and equipment support through an industrial research collaboration with Varian Medical Systems, Inc. W. S. receives research funding from Varian Medical Systems, Inc. The Department of Radiation Oncology at the Medical College of Wisconsin receives research funding from Elekta. The Department of Radiation Oncology at the Medical University of Vienna receives financial and/or equipment support for research and educational purposes from Elekta (Nucletron B.V.) and Varian Medical Systems, Inc. Dr. Kirisits has received support for educational events from Elekta (Nucletron B.V.). The Department of Radiation Oncology at Memorial Sloan‐Kettering Cancer Center receives research funding for investigator initiated clinical trials from Elekta.
Funding Information:
The TG members would like to thank Elena Nioutsikou (Siemens Healthineers), Cristina Cozzini (GE), and Mo Kadbi (formerly from Philips) for their contributions to our many phone and email discussions.
Publisher Copyright:
© 2022 American Association of Physicists in Medicine.
PY - 2022/8
Y1 - 2022/8
N2 - The task group (TG) on magnetic resonance imaging (MRI) implementation in high-dose-rate (HDR) brachytherapy (BT)—Considerations from simulation to treatment, TG 303, was constituted by the American Association of Physicists in Medicine's (AAPM's) Science Council under the direction of the Therapy Physics Committee, the Brachytherapy Subcommittee, and the Working Group on Brachytherapy Clinical Applications. The TG was charged with developing recommendations for commissioning, clinical implementation, and on-going quality assurance (QA). Additionally, the TG was charged with describing HDR BT workflows and evaluating practical consideration that arise when implementing MR imaging. For brevity, the report is focused on the treatment of gynecologic and prostate cancer. The TG report provides an introduction and rationale for MRI implementation in BT, a review of previous publications on topics including available applicators, clinical trials, previously published BT-related TG reports, and new image-guided recommendations beyond CT-based practices. The report describes MRI protocols and methodologies, including recommendations for the clinical implementation and logical considerations for MR imaging for HDR BT. Given the evolution from prescriptive to risk-based QA, an example of a risk-based analysis using MRI-based, prostate HDR BT is presented. In summary, the TG report is intended to provide clear and comprehensive guidelines and recommendations for commissioning, clinical implementation, and QA for MRI-based HDR BT that may be utilized by the medical physics community to streamline this process. This report is endorsed by the American Brachytherapy Society.
AB - The task group (TG) on magnetic resonance imaging (MRI) implementation in high-dose-rate (HDR) brachytherapy (BT)—Considerations from simulation to treatment, TG 303, was constituted by the American Association of Physicists in Medicine's (AAPM's) Science Council under the direction of the Therapy Physics Committee, the Brachytherapy Subcommittee, and the Working Group on Brachytherapy Clinical Applications. The TG was charged with developing recommendations for commissioning, clinical implementation, and on-going quality assurance (QA). Additionally, the TG was charged with describing HDR BT workflows and evaluating practical consideration that arise when implementing MR imaging. For brevity, the report is focused on the treatment of gynecologic and prostate cancer. The TG report provides an introduction and rationale for MRI implementation in BT, a review of previous publications on topics including available applicators, clinical trials, previously published BT-related TG reports, and new image-guided recommendations beyond CT-based practices. The report describes MRI protocols and methodologies, including recommendations for the clinical implementation and logical considerations for MR imaging for HDR BT. Given the evolution from prescriptive to risk-based QA, an example of a risk-based analysis using MRI-based, prostate HDR BT is presented. In summary, the TG report is intended to provide clear and comprehensive guidelines and recommendations for commissioning, clinical implementation, and QA for MRI-based HDR BT that may be utilized by the medical physics community to streamline this process. This report is endorsed by the American Brachytherapy Society.
KW - HDR
KW - MRI
KW - brachytherapy
KW - gynecological cancer
KW - prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85132581626&partnerID=8YFLogxK
U2 - 10.1002/mp.15713
DO - 10.1002/mp.15713
M3 - Article
C2 - 35662032
AN - SCOPUS:85132581626
SN - 0094-2405
VL - 49
SP - e983-e1023
JO - Medical physics
JF - Medical physics
IS - 8
ER -